The current read
Neutral, with the skew to the upside. NATiV3 can meet its primary endpoint and still leave Inventiva worth €2.62 a share against a €3.36 price, if the win is narrow: a composite gain under 10 points or a weak fibrosis result.
- We put a primary hit at 78%. On our branch values the price breaks even at 63% to 77%, depending on what a persuasive win is worth.